Karim, A., AL kafaji, H. (2025). Immunohistochemical expression of ATRX in glioma and its correlation with age,sex,tumor grade, and IDH status.. , 24(2), 259-265. doi: 10.52573/ipmj.2025.148786
Ahmed Ghanim Karim; Haider Abdul Ridha AL kafaji. "Immunohistochemical expression of ATRX in glioma and its correlation with age,sex,tumor grade, and IDH status.". , 24, 2, 2025, 259-265. doi: 10.52573/ipmj.2025.148786
Karim, A., AL kafaji, H. (2025). 'Immunohistochemical expression of ATRX in glioma and its correlation with age,sex,tumor grade, and IDH status.', , 24(2), pp. 259-265. doi: 10.52573/ipmj.2025.148786
Karim, A., AL kafaji, H. Immunohistochemical expression of ATRX in glioma and its correlation with age,sex,tumor grade, and IDH status.. , 2025; 24(2): 259-265. doi: 10.52573/ipmj.2025.148786

Immunohistochemical expression of ATRX in glioma and its correlation with age,sex,tumor grade, and IDH status.

Iraqi Postgraduate Medical Journal
Article 16, Volume 24, Issue 2, April 2025, Pages 259-265    PDF (946.77 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2025.148786
Authors
Ahmed Ghanim Karim* 1; Haider Abdul Ridha AL kafaji2
1Iraqi Board for Medical Specialties, Babylon Pathology Training Center, Iraq.
2Department of Pathology, Faculty of Medicine, University of Babylon, Babylon, Iraq.
Abstract
Background:

Gliomas are tumors deriving from glia cells and cause significant cancer mortality globally. Alpha-thalassemia/mental retardation syndrome X-linked (ATRX) mutations are frequently distinguished in gliomas.There are increasing indications to study the ATRX protein immunohistochemically to enhance knowledge about diagnosis, therapy, and prognosis.

Objective:

to determine the association between ATRX expression and different clinicopathological parameters in gliomas including age ,sex, tumor grade and IDH status.

Materials and methods:

This cross-sectional retrospective study was carried out in the Department of Pathology and Forensic Medicine, Faculty of Medicine, University of Babylon, during the period from January 2023 through December 2023. Fifty formalin-fixed and paraffin-embedded tissue blocks of patients diagnosed with glioma have been obtained from the laboratory of histopathology in Al-Kafeel Specialized Hospital, Karbala, for the last five years (2019–2023), and different clinicopathological parameters have been correlated with ATRX expression.

Results:

Loss of nuclear ATRX expression in tumor cells was observed in 37 cases (74%), while retained expression was observed in 13 cases (36%). Loss of ATRX was mostly observed in the age group of 31–40 years,while retained expression was mostly observed in age group of 61–70 years, and there was a significant association between ATRX expression and the age groups. Regarding sex, most of cases were males (54%), and there was no significant association between ATRX expression and sex.concerning tumor grade, loss of ATRX expression was observed mostly (100%) in grade 2 tumors, and there was a significant association. There was a significant association between ATRX and IDH expression

Conclusions:

Loss of nuclear ATRX expression is associated with younger patient age and a lower grade of glioma, and there is an association between IDH mutation (mutant type) and loss of ATRX expression.
Keywords
ATRX; Glioma; IDH
References
  1. Yabo YA, Niclou SP, Golebiewska A. Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. Neuro Oncol. 2022;24(5):669-82.
  2. Lee JK, Wang J, Sa JK, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet. 2017;49(4):594-99.
  3. Lucas CG, Mueller S, Reddy A, et al. Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. Neuro Oncol. 2021;23(11):1974-76.
  4. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. NeuroOncol. 2021;23(8):1231-51.
  5. Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469-74.
  6. Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review. JAMA Oncol. 2022;8(10):1493-501.
  7. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. NeuroOncol. 2021;23(8):1231-51.
  8. Pang Y, Chen X, Ji T, et al. The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer. Cancers (Basel). 2023;15(8):22-28.
  9. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma oligodendroglioma and glioblastoma. ActaNeuropathol 2015; 129:133–46.
  10. Han S, Liu Y, Cai SJ, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122(11):1580-89.
  11. Copaciu R, Rashidian J, Lloyd J, et al. Characterization of an IDH1 R132H Rabbit Monoclonal Antibody, MRQ-67, and Its Applications in the Identification of Diffuse Gliomas. Antibodies (Basel). 2023;12(1):14.
  12. . Cai J, Zhu P, Zhang C, et al. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget. 2016;7(13):16384-95.
  13. Cai J, Yang P, Zhang C, et al. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples. Oncotarget. 2014;5(9):2551-61.
  14. Haddad AF, Young JS, Oh JY,et al. The immunology of low-grade gliomas. Neurosurg Focus. 2022;52(2):E2.
  15. Testa U, Castelli G, Pelosi E. Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. Med Sci (Basel). 2018;6(4):85.
  16. Jalal JA, Rowandizy AIS, Ismael AT. Immunohistochemical expression of ATRX in gliomas.Cell MolBiol (Noisy-le-grand). 2020;66(7):131-5.
  17. Ebrahimi, A., Skardelly, M., Bonzheim, , et al. ATRX immunostaining predicts IDH and H3F3A status in gliomas. actaneuropatholcommun. 2016;4:60.
  18. Omer NS, Jalal AJ, Ismael AT. IDH1 (R132H) Immunoexpression in Glioma. JKBMS 2018; 4(1): 57-63.
  19. Cai J, Zhang C, Zhang W, et al. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience. 2016;3(7-8):258-65.
  20. Liu N, Wang P, Song H, et al. Immunostaining of IDH-1 R132H and ATRX proteins in the classification of adult glioblastomas. Int J ClinExpPathol 2016; 9(12):12849–54.
  21. Cai J, Chen J, Zhang W, et al. Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. Oncotarget. 2015;6(20):18105-15.
  22. Nandakumar P, Mansouri A, Das S. The Role of ATRX in Glioma Biology. Front Oncol. 2017;7:236.
  23. Xie Y, Tan Y, Yang C, et al. Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis. Cancer Biol Med. 2019;16(4):784-96.
  24.  
Statistics
Article View: 299
PDF Download: 146


Journal Management System. Powered by iJournalPro.com